Computer-Assisted Stop-Smoking Program in Helping Doctors Counsel Patients Who Smoke Cigarettes
Recruitment status was Recruiting
RATIONALE: A computer-assisted stop-smoking program may help doctors counsel patients who smoke and may help increase the number of patients who stop smoking.
PURPOSE: This phase II trial is studying how well a computer-assisted stop-smoking program works in helping doctors counsel patients who smoke cigarettes.
Tobacco Use Disorder
Behavioral: computer-assisted smoking cessation intervention
Other: cancer prevention
Other: educational intervention
Other: survey administration
|Study Design:||Primary Purpose: Health Services Research|
|Official Title:||Clinical Testing of a Decision Support System for Tobacco Use Treatment|
- Physician adherence to the United States Public Health Service's Tobacco Use and Dependence Treatment guideline (USPHS Guideline) as measured by the patient exit survey [ Designated as safety issue: No ]
- Patient perception of physician as measured by the patient exit survey and telephone interview [ Designated as safety issue: No ]
- Prevalence of smoking and associated variables as measured by the patient exit survey [ Designated as safety issue: No ]
- Patient interaction with the smoking cessation-personal digital assistant (SC-PDA) as measured by the patient exit survey and telephone interview [ Designated as safety issue: No ]
- Patient report of physician SC-PDA use as measured by the patient exit survey and telephone interview [ Designated as safety issue: No ]
- Aggregate data on accessing SC-PDA screens by each physician as measured by the SC-PDA server log [ Designated as safety issue: No ]
- Generation of patient handouts as measured by the SC-PDA server log, clinic staff focus groups, and telephone interview [ Designated as safety issue: No ]
- Physician self-reported use of SC-PDA as measured by physician interview [ Designated as safety issue: No ]
- Physician opinion on perceived value and barriers to use as measured by physician interview [ Designated as safety issue: No ]
- Clinic staff opinion on the effect of SC-PDA on clinic workflow as measured by clinic staff focus groups [ Designated as safety issue: No ]
|Study Start Date:||March 2009|
|Estimated Primary Completion Date:||August 2010 (Final data collection date for primary outcome measure)|
- Test the hypothesis that the clinical decision support system will improve the rate at which physicians assist their patients with smoking cessation by providing information and recommendations on smoking cessation resources.
- Assess whether exposure to information and recommendations facilitated by the smoking cessation-personal digital assistant (SC-PDA) will increase the rate at which patients make at least 1 attempt to quit smoking in the month following the physician visit.
- Assess whether exposure to information and recommendations facilitated by the SC-PDA will increase the reported use of counseling and pharmacotherapy during those attempts over that observed with a smoking status identification system alone.
- Evaluate the acceptance of the SC-PDA into the workflow of ambulatory care clinics.
OUTLINE: In weeks 1-12, physicians have access to a smoking status identification system (SSID) that reminds the physician the smoking status of the patient they are evaluating. In weeks 6-12, physicians have access to a computerized smoking cessation clinical decision support system using a hand-held personal digital assistant (SC-PDA) that they can use in the exam room with their patients who smoke. The SC-PDA system assists physicians in recommending and prescribing approved pharmacotherapy; facilitates referral of patients to local counseling resources; prints a tailored handout for a patient listing specific recommendations, instructions, and cessation resources; and generates the necessary documentation to support billing for this intervention.
Patients who visit their physician in weeks 2-6 or weeks 8-12 complete a survey after their clinic visit and undergo a telephone interview 1 month later. Physicians undergo interviews and focus groups are conducted with clinic staff in weeks 12-16.
Please refer to this study by its ClinicalTrials.gov identifier: NCT00865553
|United States, Vermont|
|Vermont Cancer Center at University of Vermont||Recruiting|
|Burlington, Vermont, United States, 05405-0110|
|Contact: Clinical Trials Office - Vermont Cancer Center at University o 802-656-2178|
|Principal Investigator:||Theodore W. Marcy, MD, MPH||University of Vermont|